Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders

Expert Opin Drug Saf. 2010 Jul;9(4):623-31. doi: 10.1517/14740331003739196.

Abstract

Importance of the field: Nervous system adverse drug reactions (NS-ADRs), such as cognitive complaints and paresthesia, are among the most frequent and clinically important ADRs of topiramate. Studying ADR profiles across disorders is clinically relevant because treatment decision-making in neuropsychiatry is highly guided by ADR profiles.

Areas covered in this review: We used medline searches (until July 2009) to review the NS-ADRs of topiramate across the most investigated topiramate indications: alcohol dependence, essential tremor, binge-eating disorder, bulimia nervosa, migraine and epilepsy. We compared NS-ADRs between these disorders but did not carry out meta-analysis.

What the reader will gain: ADR profiles greatly differed between disorders. Drop-outs due to ADRs highly varied between disorders: from 2% in the bulimia nervosa group to 29% in the migraine group. Paresthesia was the most common NS-ADR for all disorders but frequencies also differed between disorders. Cognitive complaints were frequent and were reported in comparable proportions.

Take home message: When prescribing topiramate in neuropsychiatry, physicians should be aware that NS-ADR profiles have been found to differ between disorders. Differences in drop-out rates due to ADRs and in frequencies of specific NS-ADRs across disorders must be taken into account when evaluating the potential harm of topiramate in clinical practice.

Publication types

  • Review

MeSH terms

  • Brain Diseases / drug therapy*
  • Fructose / adverse effects
  • Fructose / analogs & derivatives*
  • Fructose / therapeutic use
  • Humans
  • Mental Disorders / drug therapy*
  • Nervous System Diseases / chemically induced*
  • Neuroprotective Agents / adverse effects*
  • Neuroprotective Agents / therapeutic use
  • Paresthesia / chemically induced
  • Randomized Controlled Trials as Topic
  • Topiramate

Substances

  • Neuroprotective Agents
  • Topiramate
  • Fructose